1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CeTeG, 2009-011252-22, NCT01149109
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: NOA-07, NCT01614132
|
|
3.
|
Phase: Phase II Type: Treatment Status: Active Age: 3 to 30 at initial diagnosis Sponsor: Other Protocol IDs: CHP-693, CHP-IRB-2001-12-2301, NCI-V01-1680, NCT00031590
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 3 and over Sponsor: NCI, Other Protocol IDs: CDR0000288826, MSKCC-02088, NCT00058370
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GFPC 05-01, NCT00418743
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 00591, Eudract: 2008-007645-31, NCT00989352
|
|
7.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0597, NCT01067469
|
|
8.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000694627, EORTC-26101, EU-21103, EUDRACT-2010-023218-30, ROCHE-EORTC-26101, NCT01290939
|
|
9.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13849, H9H-MC-JBAL, NCT01582269
|
|
10.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: DepoRaCe, NCT01563614
|
|
11.
|
Phase: No phase specified Type: Treatment Status: Active Age: 0 to 21 Sponsor: Other Protocol IDs: GPOH-HIT-2000, EU-205105, NCT00303810
|